The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...
Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million people live with HIV, and each year brings 1.5 million new infections and ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...
News-Medical.Net on MSN
Improving tobacco cessation care for people living with HIV
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback